As SME IPOs gain traction among investors, regulators are moving to formalise the market with stricter controls. The NSE recently imposed a cap on SME issue listing prices at 90%, independent of grey market trends. This impacted Nephro Care, which despite a 300% pre-listing GMP, debuted at only a 90% premium due to the exchange’s price cap.
Sebi launches new verification agency to crack down on mis-selling
Sebi has launched the Past Risk and Return Verification Agency (PaRRVA) to combat mis-selling of investment products. This tech-driven system, linking credit rating agencies and